Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sharma, Amit | - |
dc.contributor.author | Kim, Eun-Joong | - |
dc.contributor.author | Mun, Seokgyu | - |
dc.contributor.author | Ji, Myung Sun | - |
dc.contributor.author | Chung, Bong Geun | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2021-09-01T16:56:02Z | - |
dc.date.available | 2021-09-01T16:56:02Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 0143-7208 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/66448 | - |
dc.description.abstract | In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | RATIOMETRIC FLUORESCENT-PROBE | - |
dc.subject | HUMAN CARBOXYLESTERASES | - |
dc.subject | DOWN-REGULATION | - |
dc.subject | CANCER-THERAPY | - |
dc.subject | PRODRUG | - |
dc.subject | NANOMEDICINE | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | SUBSTRATE | - |
dc.title | Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1016/j.dyepig.2018.12.026 | - |
dc.identifier.scopusid | 2-s2.0-85059112331 | - |
dc.identifier.wosid | 000457666300076 | - |
dc.identifier.bibliographicCitation | DYES AND PIGMENTS, v.163, pp.628 - 633 | - |
dc.relation.isPartOf | DYES AND PIGMENTS | - |
dc.citation.title | DYES AND PIGMENTS | - |
dc.citation.volume | 163 | - |
dc.citation.startPage | 628 | - |
dc.citation.endPage | 633 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Applied | - |
dc.relation.journalWebOfScienceCategory | Engineering, Chemical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Textiles | - |
dc.subject.keywordPlus | RATIOMETRIC FLUORESCENT-PROBE | - |
dc.subject.keywordPlus | HUMAN CARBOXYLESTERASES | - |
dc.subject.keywordPlus | DOWN-REGULATION | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | PRODRUG | - |
dc.subject.keywordPlus | NANOMEDICINE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | SUBSTRATE | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Theranostic | - |
dc.subject.keywordAuthor | Targeted therapy | - |
dc.subject.keywordAuthor | Drug delivery system | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.